Ritchie Karen, Lovestone Simon
Institut National de la Santé et de la Recherche Médicale, EMI 99-30, Hôpital La Colombière, Montpellier, France.
Lancet. 2002 Nov 30;360(9347):1759-66. doi: 10.1016/S0140-6736(02)11667-9.
Dementia affects about 5% of the elderly population over age 65 years and has an unexplained predominance in women and a low rate in some cultures. Different forms of dementia are now distinguished-Alzheimer's disease, dementia with Lewy bodies, frontotemporal dementia, and dementia secondary to disease, such as AIDS dementia. However, such nosological boundaries are being re-evaluated because different dementias are believed to have common underlying neuropathology. Neurochemical and neurobiological research has led to advances in understanding causes of dementia, and functional imaging has allowed identification of possible biomarkers; from these, a range of potential treatment approaches have arisen that focus on enhancement of neurotransmitter function, intervention at the level of amyloid production and deposition, and reduction of secondary risk factors such as hypertension, depression, and hypolipidaemia. Molecular diagnostic testing and genetic counselling for families with autosomal dominant early-onset dementia are new developments; however, this approach is not useful for late-onset dementia, in which the identified candidate susceptibility genes have a relatively small effect on risk. While fundamental research works towards new biological treatment strategies, much remains to be done in the area of disease management and the development of appropriate models of long-term care.
痴呆症影响着约5%的65岁以上老年人口,在女性中存在不明原因的高发情况,而在某些文化中发病率较低。现在已区分出不同类型的痴呆症——阿尔茨海默病、路易体痴呆、额颞叶痴呆以及继发于疾病(如艾滋病痴呆)的痴呆症。然而,由于人们认为不同类型的痴呆症存在共同的潜在神经病理学特征,这些疾病分类界限正在重新评估。神经化学和神经生物学研究推动了对痴呆症病因理解的进展,功能成像技术已能够识别可能的生物标志物;基于这些,出现了一系列潜在的治疗方法,这些方法侧重于增强神经递质功能、在淀粉样蛋白产生和沉积层面进行干预,以及降低高血压、抑郁症和血脂异常等继发风险因素。针对常染色体显性早发性痴呆家族的分子诊断测试和遗传咨询是新进展;然而,这种方法对晚发性痴呆症并不适用,因为已确定的候选易感基因对风险的影响相对较小。在基础研究致力于新的生物治疗策略的同时,在疾病管理领域以及开发合适的长期护理模式方面仍有许多工作要做。